The Competition Commission of India (CCI) recently ruled that a contract entered into between a hospital and a dominant player in the stem cell banking services sector was anti-competitive and had caused an appreciable adverse effect on competition in the stem cell banking market.
Ruling in Mr Ramakant Kini v Dr LH Hiranandani Hospital, Powai, Mumbai, the CCI held that the adverse effect on competition is “much more telling” as the stem cell banking services sector is at a “nascent stage in India”.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
The dispute digest is compiled by Bhasin & Co, Advocates, a corporate law firm based in New Delhi. The authors can be contacted at lbhasin@bhasinco.in or lbhasin@gmail.com. Readers should not act on the basis of this information without seeking professional legal advice.
